Exploring the Clinical Performance of Disitamab Vedotin-Keytruda Combination in Bladder Cancer
- Building on the past success of ADC-immunotherapy combination therapies
- Contextualizing Disitamab Vedotin-immunotherapy success in bladder cancer
- Outlining additional clinical DV-IO combination response in bladder cancer